Posts Tagged: prevention

Global Burden of Stroke

Global Burden of Stroke

Valery L. Feigin, Bo Norrving, George A. Mensah

Age-standardized stroke disability-adjusted life-years (DALYs) and mortality rates per 100,000 person-years in various regions of the world in 2013 (both sexes, all ages) [Powerpoint File]

Pharmacological Strategies to Retard Cardiovascular Aging

Pharmacological Strategies to Retard Cardiovascular Aging

Irene Alfaras*, Clara Di Germanio*, Michel Bernier, Anna Csiszar, Zoltan Ungvari, Edward G. Lakatta, Rafael de Cabo

Pharmacological strategies to combat cardiovascular (CV) aging. Age-associated changes in cardiac and vascular properties (depicted in the inner red circle) can be delayed by targeting the related pathways (in the middle yellow circle) with small molecules (represented in the outer blue circle). Some of the pharmacological strategies highlighted in the diagram (bold and underlined) have been shown to improve longevity in healthy mammals. AMPK indicates 5’ adenosine monophosphate–activated protein kinase; Ang-II, angiotensin II; AT1, angiotensin II receptor, type 1; Chol, cholesterol; GH, growth hormone; iACE, inhibitors of angiotensin-converting enzyme; IGF-1, insulin-like growth factor-1; mTOR, mechanistic target of rapamycin; NO, nitric oxide; NOS, nitric oxide synthase; Nrf2, NF-E2-related factor 2; PARP-1, poly(ADP-ribose) polymerase 1; PUFAs, polyunsaturated fatty acids; ROS, reactive oxygen species; and SIRT-1, sirtuin (silent mating type information regulation 2 homolog) 1. [Powerpoint File]

Pharmacological Strategies to Retard Cardiovascular Aging

Pharmacological Strategies to Retard Cardiovascular Aging

Irene Alfaras*, Clara Di Germanio*, Michel Bernier, Anna Csiszar, Zoltan Ungvari, Edward G. Lakatta, Rafael de Cabo

Antiaging effects of caloric restriction in the cardiovascular system. The up arrow notation indicates an improvement or increase, whereas the down arrow shows decrease or impairment of cardiovascular functions and pathologies. NO indicates nitric oxide. [Powerpoint FIle]

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection

Paul M Ridker

Activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome by cholesterol crystals, neutrophil extracellular traps, hypoxia, and atheroprone flow result in production of pro-interleukin (IL)-1β to IL-1β with consequent downstream effects on IL-6 and C-reactive protein (CRP), as well as increased vascular atheroma. Potential interventions include canakinumab, anakinra, tocilizumab, methotrexate, and colchicine. iNOS indicates inducible nitric oxide synthase; PAI-1, plasminogen activator inhibitor-1; and SREBP2, sterol regulatory binding protein 2. (Illustration credit: Ben Smith.) [Powerpoint File]